Brachytherapy Devices Market Size, Share & Industry Analysis, By Product (Brachytherapy Afterloader, Brachytherapy Applicators, Others), By Technique (Low Dose Rate (LDR), High Dose Rate (HDR), Pulse Dose Rate (PDR)), By Application (Prostate Cancer, Cervical Cancer, Breast Cancer, Gynaecological Cancer, Others), By End-user (Hospitals, Oncology Treatment Centres, Others) and Regional Forecast, 2023-2030

Brachytherapy is a type of radiation therapy used for the treatment of cancer. In brachytherapy, radioactive materials are placed inside patient body in order to deliver high doses of radiation to the target areas. Brachytherapy uses two type of techniques namely Low Dose Rate (LDR) and High Dose Rate (HDR). These techniques are predominantly used for the treatment of prostate cancer. Other newly developed brachytherapy techniques are Image Guided Brachytherapy (IGBT) and Pulse Dose Rate (PDR). Brachytherapy is now backed with software solutions which enable the healthcare providers for proper management and scheduling of brachytherapy for patients. The global rise in the prevalence of cancer is anticipated to increase the adoption of brachytherapy treatment. Additionally, benefits offered by brachytherapy over traditional treatment procedures such as lower treatment time and higher efficacy are likely to drive the global brachytherapy devices market.

The growth in the global brachytherapy devices market is projected to be driven by the increasing demand for brachytherapy. Moreover, certain advantages of brachytherapy such as less procedural time coupled with favourable health reimbursements are expected to offer significant growth opportunities for the brachytherapy devices market by 2026. For instance, according to the World Health Organization (WHO), the total number of cancer cases in the world in 2018 was approximately 18.1 million, also the number is estimated to reach 29.5 million by 2040.

Key Market Driver -

Increasing prevalence of cancer

Key Market Restraint -

Health risks and complications associated with exposure to radiation

Contrarily, the risk associated with the exposure to radiations is a major factor that can restrain the growth of global brachytherapy devices market. Any radiation-related theory involves health risks associated with exposure to radioactive substance. This factor could negatively harm the global brachytherapy market trend.

Key Players Covered:

The major companies covered in the global brachytherapy devices market report include Becton Dickinson and Company, GENERAL ELECTRIC COMPANY, Eckert & Ziegler BEBIG.E, Elekta AB, LifeLine Software Inc., Varian Medical Systems Inc., Panacea, RadiaDyne, C4 Imaging LLC, Cianna Medical and other players.

As per the current brachytherapy devices market trends, higher cancer patient admissions in hospitals are expected to drive growth of the hospital segment in the global brachytherapy devices market.

Key Insights:

• Epidemiology of Cancer - For Key Countries, 2018


• Overview of Reimbursement Scenario -  For Key Countries


• Key Industry Trends


• Healthcare Overview – Healthcare Expenditure of Cancer in Key Countries

Regional Analysis:

The global brachytherapy devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In North America, the brachytherapy devices market is estimated to grow in the forecast years owing to the rise in prevalence of cancer and improving health reimbursement.

To gain extensive insights into the market, Request for Customization

According to the National Cancer Institute, in 2018, approximately 1,735,350 new cases of cancer were diagnosed in the United States, implying an increase in demand for brachytherapy devices in the market. The market in Europe and Asia Pacific is likely to witness significant growth due to the rise in government initiatives and programs to cure cancer patients and improvement in medical infrastructure.

Segmentation

Brachytherapy Devices Industry Developments

• In May 2019, Takeda Pharmaceutical Company Limited announced the divestiture and sale of TachoSil to Ethicon US, LLC for US$ 400 Mn.


• In April 2016, Takeda Pharmaceutical Company Limited announced the European Union approval of TachoSil extended indication in neurosurgery.


• In March 2016, Ethicon US, LLC. announced that it has completed Phase III clinical trials of Evarrest brachytherapy devices.